Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02977286 · ClinicalTrials.gov registry record · Phase 4
Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids
A Phase 4 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT02977286: Clinical Trial Phase 4 study, sponsored by Tufts Medical Center.
NCT02977286 is a Phase 4 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 12 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02977286, a Phase 4 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study evaluates the addition of naloxegol (Movantik) to a laxative protocol in critically ill adults requiring scheduled opioid (e.g. fentanyl) therapy. Half of the participants will receive naloxegol and a laxative protocol and half the participants will receive a placebo and a laxative protocol.
Primary Outcome
Time to first spontaneous bowel movement during ICU admission after randomization
Interventions
- DRUG Placebo Oral Tablet
- DRUG Naloxegol Oral Tablet
- DRUG Docusate Sodium 100 Mg oral capsule [Colace]
- DRUG Senna 217 Mg Oral Tablet
- DRUG Polyethylene Glycols
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2019-10-09 |
| Phase | Phase 4 |
Why NCT02977286 stopped before completion
NCT02977286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo Oral Tablet is the first listed.
NCT02977286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02977286 about?
NCT02977286 is a clinical study titled "Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids". This study evaluates the addition of naloxegol (Movantik) to a laxative protocol in critically ill adults requiring scheduled opioid (e.g. fentanyl) therapy. Half of the participants will receive naloxegol and a laxative protocol and half the participants will receive a placebo and a laxative protoc...
What is the current status of trial NCT02977286?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2017-01-01. Estimated completion is 2019-10-09.
What interventions are being tested in trial NCT02977286?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Naloxegol Oral Tablet (DRUG), Docusate Sodium 100 Mg oral capsule [Colace] (DRUG), Senna 217 Mg Oral Tablet (DRUG), Polyethylene Glycols (DRUG).
Who is sponsoring clinical trial NCT02977286?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02977286's enrollment target sits among peer trials
12 1913th of 2000 higher than 70 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI